Instead, considering FOXP3+ cells, which include both CD4+/FOXP3+ cells (Treg) and CD8+/FOXP3+ cells (activated CD8 T cells), the evidence is discordant, maybe because this biomarker is expressed by immune cells involved both in tumor suppression and in tumor progression [56,57]. This evidence concerns the gene CD8A and neoplasm.